方法：将60例60眼确诊为中心凹旁型CSC患者随机分为治疗组32例32眼和对照组28例28眼，治疗组采用复方樟柳碱注射液2mL，予患眼侧颞浅动脉旁皮下注射，每日1次，对照组给予传统药物口服治疗，疗程均为2～4个疗程。以患者最佳矫正视力(BCVA)、自觉症状、视野、平均光敏感度及OCT结果为主要观察指标。

结果：治疗前两组各指标无显著性差异(P>0.05)，治疗后1，3mo治疗组各项指标均比对照组显著好转(P<0.05)，治疗后6mo两组之间均无显著性差异(P>0.05)。治疗组除个别患者有短暂口干、头晕及心慌外，未发现严重不良反应。

结论：复方樟柳碱注射液治疗中心凹旁型CSC患者的效果明显，可缩短病程，改善视功能，降低复发率。

METHODS: Sixty patients(60 eyes)who were diagnosed of juxtafoveal CSC were assigned randomly into 2 groups: 32 cases(32 eyes, therapeutic group)were injected subcutaneously compound anisodine injection for 2mL q.d around superficial temporal arteries in the affected eyes; 28 cases(28 eyes, control group)received only traditional oral medication. Both groups received therapy for 2 to 4 courses of treatment. The main observations were the best corrected visual acuity(BCVA), subjective symptom, visual field, average light sensitivity and optical coherent topography(OCT).

RESULTS: There was no significant difference between the therapeutic group and the control group before treatment(P>0.05), but all the outcome measures at 1, 3mo in the treatment group were significantly improved as compared with control group(P<0.05). After 6mo, there were no significant difference between the two groups in all measures(P>0.05). No severe adverse reaction was noted except mild ones such as temporary dry mouth, dizziness and palpitation in a few cases.

CONCLUSION: Compound anisodine injection has remarkable effects in the treatment of juxtafoveal CSC. It can shorten the course, improved the visual function and decreased the recurrence rate of CSC.